Delivery Order 75F40120D00032-75F40120F19002
Award Date
9/30/20
Potential Completion Date
9/29/21
Potential Value
$247K
Federal Agency
Food and Drug Administration
Awardee
We Pharma, Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Morrisville, NC, USA
Solicitation Procedures
Two Step
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Health and Human Services Food and Drug Administration awarded a $250,000 firm fixed price delivery order contract to We Pharma, Inc. of Morrisville, North Carolina. The purpose of this requirement is to obtain currently marketed drug products for FDA research studies. Performance will take place in Morrisville, North Carolina through September 2021. No set-aside designation was applied to this award made under an unidentified contracting vehicle. The prime contractor will...
This delivery order, awarded by the Department of Health and Human Services' Food and Drug Administration, is for $240,000 worth of pharmaceutical products to support domestic manufacturing and regulatory purposes. We Pharma, Inc. will provide the products in Takoma Park, Maryland by September 30, 2023 under a firm fixed price arrangement. As the FDA works to ensure the safety and effectiveness of drugs and medical devices, this contract will help the agency assess pharmaceutical manufacturing...
The Department of Health and Human Services Food and Drug Administration (HHS FDA) awarded a firm-fixed price delivery order to We Pharma, Inc., doing business as WEP Clinical, to obtain a reliable source of currently marketed drug products to support FDA research studies for the Generic Drug User Fee Amendments (GDUFA) regulatory science program. The $477,943.82 order, which has no set-aside designation, is part of a larger 5-year, $9.5 million indefinite delivery contract awarded to We...
The Department of Health and Human Services Food and Drug Administration (HHS FDA) awarded a firm fixed price delivery order contract to We Pharma, Inc. doing business as WEP Clinical, a self-certified small disadvantaged business, for the delivery of pharmaceutical drug products. The $182,616.74 award is in support of the FDA's research, regulatory compliance, and emergency response operations, and represents task orders under a larger 5-year, $6 million indefinite delivery contract awarded...
This is a firm fixed-price purchase order contract awarded by the Food and Drug Administration (FDA), a civilian agency within the Department of Health and Human Services, to We Pharma, Inc., a self-certified small disadvantaged business structured as a limited liability company. The contract, valued at $199,736.69, is for the procurement of drug products to support the FDA's research, regulatory, and emergency response activities. The contract is designated as a total small business...
This is a firm fixed price purchase order contract awarded by the Department of Health and Human Services (HHS) Food and Drug Administration (FDA) to We Pharma, Inc. doing business as WEP Clinical, a small disadvantaged business. The contract has a potential value of $365,000.00 and is for the delivery of physicochemical products in support of FDA research, regulatory compliance, and emergency response operations. The contract was awarded on June 29, 2018 with a completion date of July 15, 2023....
<p>The Department of Health and Human Services Food and Drug Administration (HHS FDA) awarded a $409,719 firm fixed price delivery order contract to We Pharma, Inc., doing business as WEP Clinical, for Pharmaceutical Drug Product Orders. The contract has a period of performance starting on July 31, 2023 through August 6, 2024 and will be performed in Silver Spring, Maryland.</p>
This is a new task order awarded under an existing Indefinite Delivery Indefinite Quantity (IDIQ) contract (HHSF223201610004I) with the Department of Health and Human Services Food and Drug Administration (FDA). The task order, valued at $2,470,791.00, is for a Pharmacokinetic (PK) study of opioid drug products following oral ingestion of chewed products. The study falls under the FDA's In Vivo Study of Generic Drug Products in Human Subjects program. The contract is a Firm Fixed Price...
This is a firm fixed-price delivery order awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Pfizer Inc. for $2,151,230.00 to procure pharmaceuticals to replenish expired product. The order has an ultimate completion date of September 29, 2025 and was awarded on September 30, 2024. This delivery order is not associated with a set-aside program. Pfizer, a large pharmaceutical manufacturer, is the prime contractor and has provided pharmaceuticals,...
This is a Firm Fixed Price delivery order awarded by the Food and Drug Administration (FDA) to Integrated Behavioral Health, Inc., a for-profit subchapter S corporation. The $1,024,971 contract is for data resources and surveillance reports to support post-marketing monitoring of non-medical use of pharmaceuticals and illicit drug use. The contract has a six-month performance period with a completion date of September 29, 2026. This delivery order is part of a larger $10 million FDA indefinite...